Tuesday, December 8, 2015

EDUCATION SESSIONS
12:35 p.m.

Careers in Translational Research
Geoffrey Shapiro, MD, PhD
Director, Early Drug Development Center
Clinical Director, Center for DNA Damage and Repair
Senior Physician
Dana-Farber Cancer Institute

Wednesday, December 9, 2015

EDUCATION SESSIONS
8:15 a.m.

Critical Decision Making in Radiation Therapy for Breast Cancer in 2015
Jay R. Harris, MD
Chair of the Department of Radiation Oncology at Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC)

2:15 p.m.

Hacking the Hormone Code in ER+ Breast Cancer
Myles A. Brown, MD
Physician
Director, Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute

MINI-SYMPOSIUM 1
2:15 p.m.

Beyond CDK 4/6: Targeting additional cell cycle and transcriptional CDKs in breast cancer
Geoffrey Shapiro, MD, PhD
Director, Early Drug Development Center
Clinical Director, Center for DNA Damage and Repair
Senior Physician
Dana-Farber Cancer Institute

POSTER SESSION 1
5:00-7:00 p.m.

The incidence of and survival after breast cancer recurrence
P1-07-07
Michael Hassett, MD
Dana-Farber Cancer Institute
Predisposing germline mutations in a clinic based breast cancer (BC) population
P1-08-07
Judy Garber, MD, MPH
Dana-Farber Cancer Institute

Factors associated with delays in chemotherapy initiation among patients with breast cancer
P1-12-08
Craig Bunnell, MD, MPH, MBA
Dana-Farber Cancer Institute

A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
OT1-01-06
Eric Winer, MD
Dana-Farber Cancer Institute

A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer
OT1-03-04
Sara Tolaney MD, MPH
Dana-Farber Cancer Institute

PALLAS: PALbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
OT1-03-21
Erica Mayer MD, MPH
Dana-Farber Cancer Institute
Thursday, December 10, 2015

POSTER SESSION 2
7:30-9:00 a.m.

Implementation of a breast/reconstructive surgery coordinator to reduce preoperative delays for patients undergoing mastectomy with immediate reconstruction
P2-13-12
Mehra Golshan, MD, FACS
Dana-Farber Cancer Institute

Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy
P3-07-31
Daniel Stover, MD
Dana-Farber Cancer Institute

Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance
P3-05-09
Rinath M. Jeselsohn, MD
Dana-Farber Cancer Institute

POSTER DISCUSSION 3
5:00 p.m.

PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003
Nikhil Wagle, MD
Dana-Farber Cancer Institute
Thursday, December 10, 2015

ONGOING CLINICAL TRIALS SESSION 2
5:00-7:00 p.m.

Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast cancer (BC) in postmenopausal (PM) women
OT2-01-06
Beth Overmoyer, MD
Dana-Farber Cancer Institute

The metastatic breast cancer project: A national direct-to-patient research initiative to accelerate genomics research
OT2-05-03
Nikhil Wagle, MD
Dana-Farber Cancer Institute

Friday, December 11, 2015

POSTER SESSION 4
7:30-9:00 a.m.

MRI changes in breast skin following preoperative therapy for inflammatory breast cancer (IBC)
P4-02-08
Beth Overmoyer, MD
Dana-Farber Cancer Institute

Genetic predictors of chemotherapy-related amenorrhea
P4-10-07
Ann Partridge MD, MPH
Dana-Farber Cancer Institute

Employment trends in young women following a breast cancer diagnosis
P4-10-04
Ann Partridge MD, MPH
Dana-Farber Cancer Institute
Friday, December 11, 2015

POSTER SESSION 4 (Continued)

Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
P4-13-25
Sara Tolaney, MD, MPH
Dana-Farber Cancer Institute

GENERAL SESSION 5
10:30 a.m.

Trastuzumab emtansine improves overall survival versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study
Ian Krop, MD, PhD
Dana-Farber Cancer Institute

POSTER SESSION 5
5:00-7:00 p.m.

Incidence and prognostic importance of hyponatremia in a cohort of patients with breast cancer
P5-08-49
Jorge Castillo, MD
Medical Oncology
Dana-Farber Cancer Institute

Survival benefit needed to undergo chemotherapy: Patients and physicians preferences
P5-11-02
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute

What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence
P5-12-13
Ann Partridge, MD, MPH
Dana-Farber Cancer Institute

POSTER DISCUSSION 6
5:00-7:00 p.m.

Translational Genomics - Ballroom B
Nikhil Wagle, MD, Co-Discussant
Friday, December 11, 2015

POSTER DISCUSSION 6
5:00-7:00 p.m.

Translational Genomics - Ballroom B
Nikhil Wagle, MD, Co-Discussant
Dana-Farber Cancer Institute

POSTER DISCUSSION 7
5:00-7:00 p.m.

Clinical Applications of Hereditary Multigene Panels - Ballroom A
Judy E. Garber, MD, MPH, Co-Discussant
Dana-Farber Cancer Institute

Saturday, December 12, 2015

POSTER SESSION 6
7:30-9:00 a.m.

Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer
P6-18-02
Beth Overmoyer, MD
Dana-Farber Cancer Institute

Tumor profiling of inflammatory breast cancer:
Advancing the tools needed for precision medicine
P6-18-03
Beth Overmoyer, MD
Dana-Farber Cancer Institute

9:00 a.m.

The Year in Review: Update on Basic Science Discoveries
Myles A. Brown, MD
Director, Center for Functional Cancer Epigenetics
Dana-Farber Cancer Institute